Early stages & HTS (target to lead I) 01

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/20

encourage image

There's no tags or description

Looks like no tags are added yet.

21 Terms

1
New cards

Project initiation

- Drug development considers scientific & commercial factors

- Initial assessment includes market+research analysis, competitive assessment

2
New cards

Scientific & commercial factors (project initiation)

- Unmet medical need/therapeutic opportunity

- Scientific and technical feasibility

3
New cards

Market analysis

1. Potential patient popu size

2. Disease charac's

↳ Severity + unmet med. need

↳ Acute vs. chronic

3. Existing treatments

4. Access & reimbursement considerations

<p>1. Potential patient popu size </p><p>2. Disease charac's</p><p>↳ Severity + unmet med. need </p><p>↳ Acute vs. chronic </p><p>3. Existing treatments</p><p>4. Access & reimbursement considerations</p>
4
New cards

Competitive assessment

- What are competitors developing?

1. Timing of market entry

2. Potential differentiation

<p>- What are competitors developing? </p><p>1. Timing of market entry</p><p>2. Potential differentiation</p>
5
New cards

Timing of market entry (competitive assessment)

- First-to-market may provide advantage

- Later entrants can succeed if they offer meaningful improvements

<p>- First-to-market may provide advantage </p><p>- Later entrants can succeed if they offer meaningful improvements</p>
6
New cards

Potential differentiation (competitive assessment)

- Greater efficacy

- Improved safety

- Lower cost/better access

<p>- Greater efficacy</p><p>- Improved safety</p><p>- Lower cost/better access</p>
7
New cards

Assay

Labo test or chem analysis used to measure the presence, purity, or quantity of a target substance

<p>Labo test or chem analysis used to measure the presence, purity, or quantity of a target substance</p>
8
New cards

Scientific feasibility

1./2. Is the disease+mech well understood?

3. Are biochem tools available?: reliable assays

4. Are there existing drugs?: potential starting pt, comp.

9
New cards

Lead identification + approaches

- Med. chem. requires a starting pt. → lead

- Approaches to identify hits or leads: natural prods, De-novo design, HTS

10
New cards

High-Throughput Screening (HTS)

- Rapid, efficient, automated testing of large compound libraries

- Requires a reliable, automatable assay

- Compounds showing desired activity = "hits" → re-tested & evaluated to become leads

<p>- Rapid, efficient, automated testing of large compound libraries </p><p>- Requires a reliable, automatable assay </p><p>- Compounds showing desired activity = "hits" → re-tested & evaluated to become leads</p>
11
New cards

HTS: Co's may maintain large collections containing...

- Compounds prev. synth'ed within the co. or those from commercial/ext sources

- Natural prods or natural-prod-derived compounds

<p>- Compounds prev. synth'ed within the co. or those from commercial/ext sources </p><p>- Natural prods or natural-prod-derived compounds</p>
12
New cards

Importance of testing a variety of compounds

- Hard to predict which compounds will be active

- Drug-target int's can be complex & hard to predict

- Ensures chem diversity

- ↑ chance of identifying hits

<p>- Hard to predict which compounds will be active </p><p>- Drug-target int's can be complex & hard to predict</p><p>- Ensures chem diversity </p><p>- ↑ chance of identifying hits</p>
13
New cards

HTS testing

- Compounds r initially tested under standardized screening conditions (at 1 concen.)

- Assay prods a measurable biolo response

- A predefined activity threshold to identify hits → re-tested

- Large screen can initially prod 100's of hits

- Counter-screens identify nonspecific activity or assay interference

14
New cards

Hit confirmation: removing false positives

- Many initial hits fail confirmation

- Poor solubility

- Causes of apparent activity

- Goal: confirm true activity & eliminate false/misleading hits

15
New cards

Causes of apparent activity (hit confirmation)

- Impurities or decomp. prods

- Aggregation/detergent-like behavior

- Interference w assay signal: colour or fluorescence

16
New cards

Pan-assay interference compounds (PAINS)

- Compounds w structural features associated w assay interference or nonspecific activity

- May appear active in many assays

- PAINS alerts = warning signs, not automatic proof of false activity → require extra testing to confirm true activity

17
New cards

Causes of PAINS

- Redox activity

- Chem reactivity

- Optical interference

18
New cards

Re-testing hits

1. Re-test promising hits w fresh/purified samples

2. Confirm activity is reproducible

3. Test at many concen's

4. Determine concentration-response relationship

5. More active compound → greater effect as concen ↑ up to a max. response

- Pic on desktop

<p>1. Re-test promising hits w fresh/purified samples</p><p>2. Confirm activity is reproducible</p><p>3. Test at many concen's</p><p>4. Determine concentration-response relationship</p><p>5. More active compound → greater effect as concen ↑ up to a max. response</p><p>- Pic on desktop</p>
19
New cards

Test hits in other assays

- Test confirmed hits in additional assays

- Determine if activity is:

1. Specific/selective for target

2. Nonspecific or promiscuous

- Eliminates undesirable hits before development

20
New cards

Confirm chemical structure

- Confirm identity & purity of promising hits: NMR or Mass spectroscopy

- Re-synth. compound when appropriate → ensure it retains its biolo activity

- Test structurally related compounds

- Identify structural features important for activity

<p>- Confirm identity & purity of promising hits: NMR or Mass spectroscopy </p><p>- Re-synth. compound when appropriate → ensure it retains its biolo activity</p><p>- Test structurally related compounds </p><p>- Identify structural features important for activity</p>
21
New cards

Hit-to-lead summary

1. HTS (Yes/No) → compounds become hits

2. Counter screen → reject non-specific

3. Database search → reject PAINS

4. "Routine" assay (dose-response) → reject compounds that don't show dose-response

5. Purification, re-synth, re-testing: reject compounds that "misbehave"

6. Synth & test analogs: reject compounds that don't show SAR

- Pic on desktop